Discoveries in research on diabetic keratopathy

Optometry

Volumn 72, Issue 11, 2001, Pages 691-704

  Cisarik Fredenburg, Patricia ^a  

^a UNIVERSITY OF HOUSTON   (United States)

Author keywords

Aldose reductase; Cornea; Diabetes mellitus

Indexed keywords

ALDEHYDE REDUCTASE; ENZYME INHIBITOR;

ANIMAL; CORNEA; CORNEA DISEASE; DIABETES MELLITUS; DRUG ANTAGONISM; ENZYMOLOGY; HUMAN; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; REVIEW;

ALDEHYDE REDUCTASE; ANIMALS; CORNEA; CORNEAL DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS; ENZYME INHIBITORS; HUMANS;

EID: 0035523824     PISSN: 15291839     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Foulks GN, Thoft RA, Perry D, et al. Factors related to corneal epithelial complications after closed vitrectomy in diabetics. Arch Ophthalmology 1979;97:1076-8.
2. Jeng S, Lee J-S, Huang SCM. Corneal decompensation after argon laser iridectomy - a delayed complication. Ophthalmic Surg 1991;22:565-9.
3. Ohashi Y, Matsuda M, Hosotani H, et al. Aldose Reductase inhibitor (CT-112) eyedrops for diabetic corneal epitheliopathy. Am J Ophthalmol 1988;105:233-8.
4. Perry HD, Foulks GN, Thoft RA, et al. Corneal complications after closed vitrectomy through pars plana. Arch Ophthalmol 1978;96:1401-3.
5. Fujishima H, Shimazaki J, Yagi Y, et al. Improvement of corneal sensation and tear dynamics in diabetic patients by oral aldose reductase inhibitor, ONO-2235: a preliminary study. Cornea 1996;15:368-75.
6. Yokoi N, Kinoshita S. Clinical evaluation of corneal epithelial barrier function with the slit-lamp fluorophotometer. Cornea 1995;14:485-9.
7. Gobbels M, Spitznas M, Oldendoerp J. Impairment of corneal epithelial barrier function in diabetics. Graefe's Arch Clin Exp Ophthalmol 1989;227:142-4.
8. Saini J, Khanalavla B. Corneal epithelial fragility in diabetes mellitus. Can J Ophthalmol 1995;30:142-6.
9. Tsubota K, Chiba K, Shimazaki, J. Corneal epithelium in diabetic patients. Cornea 1991;10:156-60.
10. Kinoshita JH. Aldose reductase in the diabetic eye. Am J Ophthalmol 1986;102:685-92.
11. de Kruijf EJ, Boot JP, Laterveer L, et al. Carboxyfluorescein. A simple method for determination of corneal epithelial permeability in humans. Curr Eye Res 1987; 6:1327-34.
12. Grimes P, Stone RA, Laties AM, et al. Carboxyfluorescein. A probe of the blood-ocular barriers with lower membrane permeability than fluorescein. Arch Ophthalmol 1982;100:635-9
13. LopezBernal DL, Ubels JL. Quantitative evaluation of the corneal epithelial barrier: effect of artificial tears and preservatives. Curr Eye Res 1991;10:645-56.
14. Araie M. Carboxyfluorescein. A dye for evaluating the corneal endothelial barrier function in vivo. Exp Eye Res 1986;42:141-50.
15. Watsky MA, McDermott ML, Edelhauser HF. In vitro corneal endothelial permeability in rabbit and human: the effects of age, cataract surgery, and diabetes. Exp Eye Res 1989;49:751-67.
16. Stolwijk TR, van Best JA, Boot JP, et al. Corneal epithelial barrier function after oxybuprocaine provocation in diabetics. Invest Ophthalmol Vis Sci 1990;31:436-9.
17. Azar DT, Spurr-Michaud SJ, Tisdale AS, et al. Decreased penetration of anchoring fibrils into the diabetic stroma: a morphometric analysis. Arch Ophthalmol 1989;107:1520-3.
18. Gipson IK, Spurr-Michaud SJ, Tisdale AS. Anchoring fibrils form a complex network in human and rabbit cornea. Invest Ophthalmol Vis Sci 1987;289:212-20.
19. Hyndiuk RA, Kazarian EL, Schultz RO, et al. Neurotrophic corneal ulcers in diabetes mellitus. Arch Ophthalmol 1977;95:2193-6.
20. Hosotani H, Ohashi Y, Yamada M, et al. Reversal of abnormal corneal epithelial cell morphologic characteristics and reduced corneal sensitivity in diabetic patients by aldose reductase inhibitor, CT-112. Am J Ophthalmol 1995;119:288-94.
21. Kern TS, Engerman RL. Distribution of aldose reductase in ocular tissues. Exp Eye Res 1981;33:175-82.
22. Awata T, Sogo S, Yamamoto Y. Effects of aldose reductase inhibitor, CT-112, on sugar alcohol accumulation in corneal epithelium of galactose-fed rats. Jpn J Ophthalmol 1986;30:245-50.
23. Yokoi N, Niiya A, Komuro A, et al. Effects of aldose reductase inhibitor CT-112 on the corneal epithelial barrier of galactose-fed rats. Curr Eye Res 1997;16:595-9.
24. Kubo E, Mori K, Kobayashi T, et al. Effect of aldose reductase inhibitor on corneal epithelial barrier function in galactose-fed dogs. J Ocul Pharmacol Ther 1998;14:181-90.
25. Tsubota K, Yamada M, Naoi, S. Specular microscopic observation of human corneal epithelial abnormalities. Ophthalmology 1991;98:184-91.
26. Pierro L, Brancato R, Zaganelli E. Correlation of corneal thickness with blood glucose control in diabetes mellitus. Acta Ophthalmologica (Copenh) 1993;71:169-72.
27. Goebbels M, Spitznas M. Endothelial barrier function after phacoemulsification: a comparison between diabetic and non-diabetic patients. Graefe's Arch Clin Exp Ophthalmol 1991;229:254-7.
28. Weston BC, Bourne WM, Poise KA, et al. Corneal hydration control in diabetes nellitus. Invest Ophthalmol Vis Sci 1995;36:586-95.
29. Herse PR. Diurnal and long-term variations in corneal thickness in the normal and alloxan-induced diabetic rabbit. Curr Eye Res 1990;9:451-7.
30. Ravalico G, Tognetto D, Palomba M, et al. Corneal endothelial function in diabetes: a fluorophotometric study. Ophthalmologica 1994;208:179-84.
31. Herse P and Hooker B. Corneal edema recovery dynamics in diabetes: is the alloxan-induced diabetic rabbit a useful model? Invest Ophthalmol Vis Sci 1994;35:310-3.
32. Larsson L-I, Bourne WM, Pach JM, et al. Structure and function of the corneal endothelium in diabetes mellitus type I and type II. Arch Ophthalmol 1996;114:9-14.
33. McNamara NA, Brand RJ, Polse KA, et al. Corneal function during normal and high serum glucose levels in diabetes. Invest Ophthalmol Vis Sci 1998;39:3-17.
34. Datiles MB, Kador PF, Kashima K, et al. The effects of sorbinil, an aldose reductase inhibitor, on the corneal endothelium in galactosemic dogs. Invest Ophthalmol Vis Sci 1990;31:2201-4.
35. Herse PR. Corneal hydration control in normal and alloxan-induced diabetic rabbits. Invest Ophthalmol Vis Sci 1990;31:2205-2213.
36. Rao GN, Shaw EL, Arthur EJ, et al. Endothelial cell morphology and corneal deturgence. Ann Ophthalmol 1979; 11:885-99.
37. Kim EK, Geroski DH, Holley GP, et al. Corneal endothelial cytoskeletal changes in F-actin with aging, diabetes, and after cytochalasin exposure. Am J Ophthamol 1992;114:329-35.
38. Schultz RO, Matsuda M, Yee RW, et al. Corneal endothelial changes in type I and type II diabetes mellitus. Am J Ophthalmol 1984;98:401-10.
39. Schwartz AL, Martin NF, Weber PA. Corneal decompensation after argon laser iridectomy. Arch Ophthalmol 1988;106:1572-4.
40. Pardos GJ and Krachmer JH. Comparison of endothelial cell density in diabetics and a control population. Am J Ophthalmol 1980;90:172-4.
41. Polse KA, Brand RJ, Cohen SR, et al. Hypoxic effects on corneal morphology and function. Invest Ophthalmol Vis Sci 1990;31:1542-54.
42. Pfeiffer A, Spranger J, Meyer-Schwickerath R, et al. Growth factor alterations in advanced diabetic retinopathy: a possible role of blood retina barrier breakdown. Diabetes 1997;46(Suppl 2):S26-30.
43. Makitie J, Koskenvuo M, Vannas A, et al. Corneal endothelium after photocoagulation in diabetic patients. Acta Ophthalmologica (Copenh) 1985;63:355-60.
44. Lass JH, Spurney RV, Dutt RM, et al. A morphologic and fluorophotometric analysis of the corneal endothelium in type I diabetes mellitus and cystic fibrosis. Am J Ophthalmol 1985;100:783-8.
45. Furuse N, Hayasaka S, Yamamoto Y, et al. Corneal endothelial changes after posterior chamber intraocular lens implantation in patients with or without diabetes mellitus. Br J Ophthalmol 1990;74:258-60.
46. Matsuda M, Awata T, Ohashi Y, et al. The effects of aldose reductase inhibitor on the corneal endothelial morphology in diabetic rats. Curr Eye Res 1987;6:391-7.
47. Meyer LA, Ubels JL, Edelhauser HF. Corneal endothelial morphology in the rat: effects of aging, diabetes, and topical aldose reductase inhibitor treatment. Invest Ophthalmol Vis Sci 1988;29:940-8.
48. Keoleian GM, Pach JM, Hodge DO, et al. Structural and functional studies of the corneal endothelium in diabetes mellitus. Am J Ophthalmol 1992;113:64-70.
49. Saini J, Mittal S. In vivo assessment of corneal endothelial function in diabetes mellitus. Arch Ophthalmol 1996; 114:649-53.
50. Whikehart DR, Montgomery B, Angelos P, et al. Alteration of ATPase activity and duplex DNA in corneal cells grown in high glucose media. Cornea 1993;12:295-8.
51. Colodny L and Hoffman RL. Inositol clinical applications for exogenous use. Altern Med Rev 1998;3:432-47.
52. Loy A, Lurie KG, Ghosh A, et al. Diabetes and the myoinositol paradox. Diabetes 1990;39:1305-12.
53. Ohguro N, Matsuda M, Ohashi Y, et al. Topical aldose reductase inhibitor for correcting corneal endothelial changes in diabetic patients. Br J Ophthalmol 1995; 79:1074-7.
54. Sanchez-Thorin JC. The cornea in diabetes mellitus. Int Ophthalmol Clin 1998;38:19-36.